RMD
ResMed Inc.
- Healthcare
- US companies in Healthcare (47)
- NYSE · USD
- Mkt cap $35.6bn
$252.83
as of 29 Oct 2026, 9% below its 52-week high
Screens as well placed to keep growing its dividend, though with some cut-risk signals worth watching. Its valuation looks somewhat extended against its own history.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 0.97%Last 12 months of regular payments at today's price
- Forward yield
- 1.07%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- 2.6×Pays 39% of earnings
- Cash cover
- 4.6×Free cash flow over dividends paid
- 5y dividend growth
- +9.0% a yearNo cut since FY2014
- Next ex-dividend date
- Estimated13 Nov 2026Quarterly dividend of about $0.66
Compared with US companies in Healthcare (47)
- Trailing yield is higher than 24 of the 46 other US companies in Healthcare.
- 5y dividend growth (as paid) is higher than 25 of the 38 other US companies in Healthcare with a 5y growth figure.
Quality
96
HighCapacity to keep growing the dividend
Risk
50
ModerateSignals of dividend-cut pressure
Trim
62
ModerateHow extended the valuation looks
Why Risk is 50
RMD against US companies in Healthcare (47)
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of RMD’s past readings.
- P/E18.5×P0, good for this measure
- Yield1.23%P69, neutral for this measure
- FCF payout21.2%P14, good for this measure
- Net debt / EBITDA-0.30P3, good for this measure
- DGR 5y+9.0%P81, good for this measure
- ROIC19.7%P83, good for this measure
Forecast your income with the RMD dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.